Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis

Table 1 Baseline characteristics of the 296 patients with stage III-IVB nasopharyngeal carcinoma

Characteristics	Investigational arm (N = 149, %)	Control arm (N = 147, %)	P-value^a
Gender			0.419
Male	116 (77.9)	120 (81.6)
Female	33 (22.1)	27 (18.4)
Age (years)			0.544
Median (IQR)	42 (36–51)	43 (36–52)
Smoking			0.491
Yes	57 (38.3)	62 (42.2)
No	92 (61.7)	85 (57.8)
Drinking			0.095
Yes	30 (20.1)	19 (12.9)
No	119 (79.9)	128 (87.1)
Family history of cancer			0.668
Yes	47 (31.5)	43 (29.3)
No	102 (68.5)	104 (70.7)
LDH (U/L)			0.336
Median (IQR)	175 (154–216)	184 (161–215)
Pre-DNA^b			0.957
Median (IQR)	6880 (106–77,950)	7445 (494–52,050)
T category^c			0.112
T1	6 (4.0)	1 (0.7)
T2	7 (4.7)	14 (9.5)
T3	81 (54.4)	77 (52.4)
T4	55 (36.9)	55 (37.4)
N category^c			0.873
N0	7 (4.7)	9 (6.1)
N1	49 (32.9)	48 (32.7)
N2	61 (40.9)	63 (42.9)
N3	32 (21.5)	27 (18.3)
Overall stage^c			0.819
III	71 (47.7)	72 (49.0)
IVA-B	78 (52.3)	75 (51.0)
TPF regimen (cycles)			0.484
Two	15 (30.0)	14 (41.6)
Three	33 (66.0)	18 (50.3)
Four	2 (4.0)	2 (8.1)
PF regimen (cycles)			0.495
Two	42 (93.3)	51 (96.3)
Three	3 (6.7)	6 (2.9)
Four	0 (0)	0 (0)
TP regimen (cycles)			0.31
Two	43 (79.6)	45 (59.9)
Three	7 (13.0)	10 (34.0)
Four	4 (7.4)	1 (6.1)
Concurrent chemotherapy			0.964
Yes	130 (87.2)	128 (87.1)
No	19 (12.8)	19 (12.9)

IC induction chemotherapy, IQR interquartile, LDH lactate dehydrogenase; Pre-DNA pre-treatment Epstein-Barr virus DNA, TPF docetaxel plus cisplatin with fluorouracil, PF cisplatin with fluorouracil, TP docetaxel with cisplatin
^aP-values were calculated using Chi-square test for categorical variables and Mann-Whitney test for continuous variables
^bThree patients in the control arm did not have this data
^cAccording to the 7th edition of the International Union against Cancer/American Joint Committee on Cancer (UICC/AJCC) system

ISSN: 1471-2407